Clinical Evidence and Information
Trudell Medical International has an enviable history of strong leadership in creating innovative medical devices that enhance the quality of life for people of all ages - all backed by science and clinical evidence.
Use the tabs below to find the latest clinical information regarding AeroChamber Plus* Flow-Vu* Chamber and the Aerobika* Oscillating Positive Expiratory Pressure Device.
The AeroChamber* Brand of Valved Holding Chamber (VHC) has been continually updated and improved upon since it was first introduced in 1983. The product enhancements are designed to increase ease of use for patients while enhancing the consistency of aerosol medication delivery.
A brief overview of the latest clinical information regarding AeroChamber* Brand of VHC.
Presented at the British Thoracic Society December 2018.
Having a child with asthma can be stressful for parents, especially for financially strapped ones struggling to pay for an arsenal of puffers and pills for their child’s treatment. Because of this, those healthcare professionals who recommend spacer chambers may suggest one of many lower-cost versions that are available on the market today. But focusing only on cost may be putting a child’s health at risk.
According to this new retrospective study, published in Pulmonary Therapy, the AeroChamber Plus* Flow-Vu* Anti-Static VHC was associated with a significant delay in time to first exacerbation (p=0.0005) and a significant 13% reduction in Emergency Room/Accident and Emergency (ER/A&E) visits (p=0.0167) compared with control, non-anti-static chambers.
Presented at ATS 2021
Conclusions:
- The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
- The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
The following sections are included in the summary:
- The Problem with Airway Maintenance in Chronic Obstructive Pulmonary Disease
An overview of the effect structure-function decline has on the airways of patients with COPD - Studies Using the Aerobika* Device
In vitro and in vivo studies supporting the efficacy of the Aerobika* device - Airway Maintenance in COPD, Bronchiectasis and Cystic Fibrosis
Articles addressing the use and efficacy of Airway Clearance Techniques as part of an overall therapy program in Chronic Obstructive Pulmonary Disease, Bronchiectasis and Cystic Fibrosis - Guidelines
International guidelines recommending the use of PEP and Oscillating PEP
A brief overview of the latest clinical information regarding the Aerobika* device.
The effectiveness of the Aerobika* device in COPD treatment was recently included in a comprehensive review, analyzing 20 years of data.
Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the Aerobika* oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.